The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study

被引:40
作者
Erdal, Gulcin Sahingoz [1 ]
Polat, Ozlem [2 ]
Erdem, Gokmen Umut [1 ]
Korkusuz, Ramazan [3 ]
Hindilerden, Fehmi [4 ]
Yilmaz, Mesut [1 ]
Yasar, Kadriye Kart [3 ]
Isiksacan, Nilgun [5 ]
Tural, Deniz [1 ]
机构
[1] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Oncol, Dr Tevfik Saglam St 11, TR-34147 Istanbul, Turkey
[2] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Family Med, Istanbul, Turkey
[3] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey
[4] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Hematol, Istanbul, Turkey
[5] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Biochem, Istanbul, Turkey
关键词
COVID-19; Cancer; Mortality rate; Retrospective case study; RISK;
D O I
10.1007/s10147-021-01863-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Coronavirus disease 2019 (COVID-19) has quickly turned into a global pandemic with close to 5 million cases and more than 320,000 deaths. Cancer patients constitute a group that is expected to be at risk and poor prognosis in COVID pandemic. We aimed to investigate how cancer patients are affected by COVID-19 infection, its clinical course and the factors affecting mortality. Methods In our single-center retrospective study, we included cancer patients with laboratory confirmed COVID-19 in our hospital. Demographic, clinical, treatment, and laboratory data were obtained from electronic medical records. Logistic regression methods were used to investigate risk factors associated with in-hospital death. Results In the hospital, 4489 patients were hospitalized with COVID infection and 77 were cancer patients. The mean age of cancer patients was 61.9 +/- 10.9 and 44 of them were male (62%). While the mortality rate in non-cancer patients was 1.51% (n = 68), this rate was significantly higher in cancer patients, 23.9% (n = 17). The stage of the disease, receiving chemotherapy in the last 30 days also lymphopenia, elevated troponin I, d-dimer, CRP, and CT findings were associated with severe disease and mortality. Severe lung involvement (OR = 22.9, p = 0.01) and lymphopenia (OR = 0.99, p = 0.04) are the most important factors influencing survival in logistic regression. Conclusions The disease is more severe in cancer patients and mortality is significantly higher than non-cancer patients. These data show that it may be beneficial to develop dynamic prevention, early diagnosis and treatment strategies for this vulnerable group of patients who are affected by the infection so much.
引用
收藏
页码:826 / 834
页数:9
相关论文
共 24 条
  • [1] [Anonymous], 2020, CORONAVIRUS UPDATES
  • [2] High D-dimer levels are associated with poor prognosis in cancer patients
    Ay, Cihan
    Dunkler, Daniela
    Pirker, Robert
    Thaler, Johannes
    Quehenberger, Peter
    Wagner, Oswald
    Zielinski, Christoph
    Pabinger, Ingrid
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08): : 1158 - 1164
  • [3] Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
    Dai, Mengyuan
    Liu, Dianbo
    Liu, Miao
    Zhou, Fuxiang
    Li, Guiling
    Chen, Zhen
    Zhang, Zhian
    You, Hua
    Wu, Meng
    Zheng, Qichao
    Xiong, Yong
    Xiong, Huihua
    Wang, Chun
    Chen, Changchun
    Xiong, Fei
    Zhang, Yan
    Peng, Yaqin
    Ge, Siping
    Zhen, Bo
    Yu, Tingting
    Wang, Ling
    Wang, Hua
    Liu, Yu
    Chen, Yeshan
    Mei, Junhua
    Gao, Xiaojia
    Li, Zhuyan
    Gan, Lijuan
    He, Can
    Li, Zhen
    Shi, Yuying
    Qi, Yuwen
    Yang, Jing
    Tenen, Daniel G.
    Chai, Li
    Mucci, Lorelei A.
    Santillana, Mauricio
    Cai, Hongbing
    [J]. CANCER DISCOVERY, 2020, 10 (06) : 783 - 791
  • [4] Dignani Maria Cecilia, 2014, F1000Res, V3, P221, DOI 10.12688/f1000research.5251.2
  • [5] Emami A, 2020, ARCH ACAD EMERG MED, V8, DOI 10.22037/aaem.v8i1.600
  • [6] Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
    Gao, Yong
    Li, Tuantuan
    Han, Mingfeng
    Li, Xiuyong
    Wu, Dong
    Xu, Yuanhong
    Zhu, Yulin
    Liu, Yan
    Wang, Xiaowu
    Wang, Linding
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) : 791 - 796
  • [7] Clinical Characteristics of Coronavirus Disease 2019 in China
    Guan, W.
    Ni, Z.
    Hu, Yu
    Liang, W.
    Ou, C.
    He, J.
    Liu, L.
    Shan, H.
    Lei, C.
    Hui, D. S. C.
    Du, B.
    Li, L.
    Zeng, G.
    Yuen, K. -Y.
    Chen, R.
    Tang, C.
    Wang, T.
    Chen, P.
    Xiang, J.
    Li, S.
    Wang, Jin-lin
    Liang, Z.
    Peng, Y.
    Wei, L.
    Liu, Y.
    Hu, Ya-hua
    Peng, P.
    Wang, Jian-ming
    Liu, J.
    Chen, Z.
    Li, G.
    Zheng, Z.
    Qiu, S.
    Luo, J.
    Ye, C.
    Zhu, S.
    Zhong, N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18) : 1708 - 1720
  • [8] The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia
    Li, Kunhua
    Wu, Jiong
    Wu, Faqi
    Guo, Dajing
    Chen, Linli
    Fang, Zheng
    Li, Chuanming
    [J]. INVESTIGATIVE RADIOLOGY, 2020, 55 (06) : 327 - 331
  • [9] Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
    Liang, Wenhua
    Guan, Weijie
    Chen, Ruchong
    Wang, Wei
    Li, Jianfu
    Xu, Ke
    Li, Caichen
    Ai, Qing
    Lu, Weixiang
    Liang, Hengrui
    Li, Shiyue
    He, Jianxing
    [J]. LANCET ONCOLOGY, 2020, 21 (03) : 335 - 337
  • [10] Prognostic value of interleukin-6, C -reactive protein, patients with COVID-19 and procalcitonin in
    Liu, Fang
    Li, Lin
    Xu, MengDa
    Wu, Juan
    Luo, Ding
    Zhu, YuSi
    Li, BiXi
    Song, XiaoYang
    Zhou, Xiang
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2020, 127